A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration approval for a form of breast cancer, the first U.S. approval for a drug for which the companies have high expectations.
The FDA announced Friday that it had approved the drug, which will be marketed as Datroway, for certain patients with advanced breast cancer. Datroway, also called datopotamab deruxtecan, or Dato-DXd, was approved in Japan for a form of breast cancer last month, its first regulatory green light.
The list price of Datroway in the United States is approximately $4,900 per 100-milligram vial, and the recommended dose of the drug is 6 milligrams per kilogram of the patient’s weight every three weeks.
Already have an account? Log in
See all packages
Support our sports cover in high school by becoming a digital subscriber. Subscribe nowOrange county…
The US State Department will use artificial intelligence to revoke the visas of foreign students…
The Mega Rocket Starship of SpaceX is making a test flight from Starbase to Boca…
The story is always the same: I get a new pair of sneakers and I…
"You have challenged Europe to intensify. You have challenged us to intensify Ukraine, for defense…